CN103191343A - Pharmaceutical composition for treating diaphyseal aclasis - Google Patents
Pharmaceutical composition for treating diaphyseal aclasis Download PDFInfo
- Publication number
- CN103191343A CN103191343A CN2013101077947A CN201310107794A CN103191343A CN 103191343 A CN103191343 A CN 103191343A CN 2013101077947 A CN2013101077947 A CN 2013101077947A CN 201310107794 A CN201310107794 A CN 201310107794A CN 103191343 A CN103191343 A CN 103191343A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- fructus
- brown
- parched
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a pharmaceutical composition for treating diaphyseal aclasis. The pharmaceutical composition is applied to the treatment of diaphyseal aclasis. The pharmaceutical composition is characterized by being prepared from the following raw pharmaceutical materials in proportioning ratio by weight: litchi chinensis Sonn., poncirus tuifoliata (L.) Raf., trachelospermum jasminoides (Lindl.) Lem., luffa cylindrica (L.) Roem., murraya jasminorage, polygonum orientale L., radix platycodi, radix puerariae, paris polyphylla Sm., diplazium lanceum (Thunb.) Presl, hordeum vulgare L. and setaria italica (L.) Beauv.. Proved by clinical trials, the pharmaceutical composition has the characteristics of good treatment effect and high safety in the adjuvant treatment of diaphyseal aclasis, so that the pharmaceutical composition is worthy of clinical application and popularization.
Description
Technical field
The present invention relates to the drug use in osteopathy field, be specifically related to a kind of pharmaceutical composition for the treatment of diaphyseal aclasis.
Background technology
Diaphyseal aclasis (diaphyseal aclasis) is a kind of dysplasia of cartilage.Show as multiple exostosis and metaphysis deformity, therefore also claim metaphyseal dysplasia (metaphysialaclasis).Primary disease rises from enchondral ossification and the membrane-enclosed bone of bone is arranged, the position of especially falling in osteogenesis work, i.e. distal part of femur, proximal tibia, ulna far-end.
Still lack at present the therapeutic scheme sick for this, only affect joint motion and compressing tendon when neural, capable surgical removal.But because diaphyseal aclasis rises from metaphysis, if do not treated, often cause the skeleton development obstacle, often cause long bone of limbs cripetura or deformity, of short and small stature.
Summary of the invention
Technical assignment of the present invention is for above the deficiencies in the prior art, provides a kind of curative effect certainly and the pharmaceutical composition of the diaphyseal aclasis that side effect is little.
The technical scheme that the present invention solves its technical problem is: a kind of pharmaceutical composition for the treatment of diaphyseal aclasis is characterized in that being prepared from by the crude drug of following weight proportion: 10 ~ 30 parts of Semen Litchis, 6 ~ 12 parts of Cortex Ponciri trifoliatae, 6 ~ 12 parts of Caulis Trachelospermis, 6 ~ 12 parts of Retinervus Luffae Fructuss, 1 ~ 5 part of Folium Et Cacumen Murrayae, 3 ~ 10 parts of Fructus Polygoni Orientaliss, 6 ~ 12 parts of Radix Platycodoniss, 6 ~ 12 parts of Radix Puerariaes, 6 ~ 12 parts of Rhizoma Paridis, 3 ~ 10 parts of Diplazium lanceum (Thunb)s, 3 ~ 10 parts of Fructus Hordei Germinatus (parched to brown)s, 10 ~ 25 parts of Fructus Setariae Germinatus (parched to brown).
Chinese medicine of the present invention is that the raw material by following optimum weight part proportioning is prepared from: 20 parts of Semen Litchis, 10 parts of Cortex Ponciri trifoliatae, 10 parts of Caulis Trachelospermis, 10 parts of Retinervus Luffae Fructuss, 2 parts of Folium Et Cacumen Murrayae, 6 parts of Fructus Polygoni Orientaliss, 10 parts of Radix Platycodoniss, 10 parts of Radix Puerariaes, 10 parts of Rhizoma Paridis, 6 parts of Diplazium lanceum (Thunb)s, 6 parts of Fructus Hordei Germinatus (parched to brown)s, 20 parts of Fructus Setariae Germinatus (parched to brown).
Wherein said:
Semen Litchi is the dry mature seed of sapindaceous plant Fructus Litchi Litchi chinensis Sonn..Sweet, the micro-hardship of nature and flavor, temperature.Return liver, kidney channel.But the merit promoting QI to circulate and dispersing the agglomeration of the pathogens, cold-dispelling pain-relieving.
Cortex Ponciri trifoliatae is bark bits or the peel bits of rutaceae Fructus Ponciri Trifoliatae (Fructus Ponciri Trifoliatae Immaturus) Poncirus tuifoliata (L.) Raf..The nature and flavor suffering; Temperature.Return liver; Kidney channel.But merit endogenous wind stopping relieving convulsion; Eleminating phlegm and freeing channels.Mainly cure apoplexy, orthotonus; Joint stuffiness; facial hemiparalysis.
Fructus Polygoni Orientalis is the dry mature fruit of polygonaceae plant smartweed Polygonum orientale L..Salty, be slightly cold.Return liver, stomach warp.The merit blood eliminating mass of can faling apart, the removing food stagnancy pain relieving.
The dried roots that Radix Platycodonis is Campanulaceae Radix Platycodonis, but merit expelling phlegm for arresting cough, and lung qi dispersing, evacuation of pus effect are arranged.
Diplazium lanceum (Thunb) is the stem pith of leguminous plant Herba Aeschynonenes Indicae stem Aeschynomene indica L..Nature and flavor are bitter, flat.Attach to the lung and stomach meridians.Heat clearing away, diuresis, lactogenesis, improving eyesight.
Diplazium lanceum (Thunb) is herb, the root stock of fern Athyriaceae lance leaf female dragon Diplazium lanceum (Thunb.) Presl.Sweet, hot, micro-hardship, cold.Clearing away heat and cooling blood, diuresis.
Radix Puerariae, the root that Radix Puerariae is the leguminous plant Pachyrhizua angulatus.Sweet, hot, flat.Enter spleen, the stomach warp.Merit can be induced sweat, rash, and relaxing muscles and tendons, promote the production of body fluid, antidiarrheal.
Rhizoma Paridis is the rhizome of liliaceous plant Rhizoma Paridis Paris polyphylla Sm..Hardship, be slightly cold.Enter Liver Channel.But the merit heat-clearing and toxic substances removing, detumescence, spasmolytic.
Retinervus Luffae Fructus is the vascular bundle of the dry mature fruit of cucurbitaceous plant Fructus Luffae Luffa cylindrica (L.) Roem..Sweet, flat.Return lung, stomach, Liver Channel.But the merit dredging collateral, invigorate blood circulation, and dispels the wind.
Folium Et Cacumen Murrayae is dried leaves and the band leaf twig of rutaceae Folium Et Cacumen Murrayae Murraya exotica L. and Murraya paniculata (L.) Jack. Murraya paniculata (L.) xJack.Hot, micro-hardship, temperature.The promoting flow of QI and blood dissipating blood stasis, relieving convulsion, removing toxic substances and promoting subsidence of swelling, Eradicates wind is active.
Fructus Hordei Germinatus (parched to brown),, fry to burnt brown according to the method for frying through the drying of germinateing for the mature fruit of grass Fructus Hordei Vulgaris Hordeum vulgare L., cools sieve dedust bits.Nature and flavor are sweet, flat.Return spleen, stomach warp.But the merit promote qi circulation digestion promoting, spleen benefiting and stimulating the appetite, move back newborn relieving distension.
Fructus Setariae Germinatus (parched to brown),, fry to burnt brown according to frying method through the drying of germinateing for the mature fruit of grass foxtail millet Setaria italica (L.) Beauv..Nature and flavor are sweet, temperature.Return spleen, stomach warp.Merit can help digestion and in, spleen benefiting and stimulating the appetite.
Composition principle: diaphyseal aclasis is a kind of benign bone tumour, at present the sick medicine without this clinically.The inventor is through the discovery of clinical research for many years, and the pathogeny of diaphyseal aclasis is " the irregular division of chondo-epiphysial cells ", and draws prescription disclosed by the invention through repetition test deliberation checking.
Compared with prior art, the present invention has following characteristics.
1, prescription uniqueness: the inventor thinks that primary disease is that expectorant folder blood stasis forms, phlegm and blood stasis, and the glue work is for suffering from, and should invigorate blood circulation, eliminates the phlegm, eliminating stagnation, dredging collateral go forward side by side, and can improve the pathology present situation of the irregular division of diaphyseal aclasis epiphysis ossification center's chondo-epiphysial cells; Avoid using the medicine of nourishing liver and kidney in side, especially avoid the product that use flesh and blood in love, it is abnormal that its reason is that such medicine can not improve skeletonization, on the contrary because " mending it not empty " causes accumulated heat in interior, promotes PD; So get Semen Litchi, Cortex Ponciri trifoliatae in side for monarch, Semen Litchi can enter the joint epiphysis, promoting QI to circulate and dispersing the agglomeration of the pathogens, cold-dispelling pain-relieving; Cortex Ponciri trifoliatae endogenous wind stopping relieving convulsion, eleminating phlegm and freeing channels, clinical former multiplex in apoplexy sequela, but the inventor experimental studies have found that, low dose of Cortex Ponciri trifoliatae water decoction or volatile oil all have protective effect for the chondo-epiphysial cells in cell culture; The capable loose power of described Semen Litchi is strong, and Cortex Ponciri trifoliatae is from expectorant from wind, the two cooperation, and constant breathing, reduce phlegm by endogenous wind stopping on the one hand and solve the problem of epiphysis skeletonization center island skeletonization inequality, can pass through on the other hand dredging collateral dissipating blood stasis alleviating pain, the alleviation clinical symptoms.
2, blood system medicine Caulis Trachelospermi, Retinervus Luffae Fructus, Folium Et Cacumen Murrayae, except the removing heat from blood and promoting blood circulation effect, all have the dredging collateral effect, and a medicine multiple-effect, contribute to reduce medicament categories and consumption, do not increase the Liver and kidney burden.
3, sucutaneous nodule condenses in the joint epiphysis, so the present invention writes out a prescription, with Fructus Polygoni Orientalis, Radix Platycodonis, coordinates the broken knot of Cortex Ponciri trifoliatae to reduce phlegm.
4, Radix Puerariae relaxing muscles and tendons, Rhizoma Paridis spasmolytic, Folium Et Cacumen Murrayae row are altered actively, and three medicine combineds effect are organized spasm in the hope of alleviating periarticular, reduce epiphysis periphery ligament tractive tension force, increase epiphysis stability.
5, get the Diplazium lanceum (Thunb) mechanism of qi in we and open entirely, increase the transdermal absorption factor of other drug; And the use of Fructus Hordei Germinatus (parched to brown) and Fructus Setariae Germinatus (parched to brown) is considered from reducing local excitation.
6, medicine material consumption of the present invention is groped in a large number to sum up through the inventor and is drawn, each raw material consumption is for all to have curative effect preferably in the following weight parts scope: the Semen Litchi amount is larger, the inventor studies discovery, only has escalated dose Semen Litchi side drug effect to enter the joint epiphysis; In " China book on Chinese herbal medicine ", dosage of record Cortex Ponciri trifoliatae is 15 ~ 30g, and in this prescription, Cortex Ponciri trifoliatae be low dose, and its reason is, heavy dose is apoplexy sequela, and in we, is solid protection cartilage proper splitting ossification.And the dosage of Folium Et Cacumen Murrayae is very little, reason be the Folium Et Cacumen Murrayae of middle heavy dose for narcotic analgesic, be that row alters actively and get the Folium Et Cacumen Murrayae effect in we, without heavy dose, slightly get final product.
The specific embodiment
Below in conjunction with practical situation, the specific embodiment of the present invention is elaborated.
Embodiment 1, the crude drug weight proportion: Semen Litchi 20g, Cortex Ponciri trifoliatae 10g, Fructus Polygoni Orientalis 6g, Radix Platycodonis 10g, Diplazium lanceum (Thunb) 6g, Caulis Trachelospermi 10g, Radix Puerariae 10g, Rhizoma Paridis 10g, Retinervus Luffae Fructus 12g, Folium Et Cacumen Murrayae 2g, Fructus Hordei Germinatus (parched to brown) 6g, Fructus Setariae Germinatus (parched to brown) 20g.
The preparation method of embodiment 1 is: Semen Litchi, Cortex Ponciri trifoliatae, Fructus Polygoni Orientalis, Radix Platycodonis, Diplazium lanceum (Thunb), Caulis Trachelospermi, Radix Puerariae, Rhizoma Paridis, Retinervus Luffae Fructus, Folium Et Cacumen Murrayae, Fructus Hordei Germinatus (parched to brown), Fructus Setariae Germinatus (parched to brown) mixing and water adding are decocted, get filtrate after 30 minutes, medicinal residues add water continuation decoction and get filtrate after 20 minutes, twice filtrate merges, and is divided into two parts of affected part hot-wet compresss sooner or later.
Embodiment 2, the crude drug weight proportion: 10 parts of Semen Litchis, 6 parts of Cortex Ponciri trifoliatae, 3 parts of Fructus Polygoni Orientaliss, 6 parts of Radix Platycodoniss, 3 parts of Diplazium lanceum (Thunb)s, 6 parts of Caulis Trachelospermis, 6 parts of Radix Puerariaes, 6 parts of Rhizoma Paridis, 6 parts of Retinervus Luffae Fructuss, 1 part of Folium Et Cacumen Murrayae, 3 parts of Fructus Hordei Germinatus (parched to brown)s, 10 parts of Fructus Setariae Germinatus (parched to brown).
Embodiment 3, the crude drug weight proportion: 20 parts of Semen Litchis, 10 parts of Cortex Ponciri trifoliatae, 6 parts of Fructus Polygoni Orientaliss, 10 parts of Radix Platycodoniss, 6 parts of Diplazium lanceum (Thunb)s, 10 parts of Caulis Trachelospermis, 10 parts of Radix Puerariaes, 10 parts of Rhizoma Paridis, 10 parts of Retinervus Luffae Fructuss, 2 parts of Folium Et Cacumen Murrayae, 6 parts of Fructus Hordei Germinatus (parched to brown)s, 20 parts of Fructus Setariae Germinatus (parched to brown).
Embodiment 4, the crude drug weight proportion: 30 parts of Semen Litchis, 12 parts of Cortex Ponciri trifoliatae, 10 parts of Fructus Polygoni Orientaliss, 12 parts of Radix Platycodoniss, 10 parts of Diplazium lanceum (Thunb)s, 12 parts of Caulis Trachelospermis, 12 parts of Radix Puerariaes, 12 parts of Rhizoma Paridis, 12 parts of Retinervus Luffae Fructuss, 5 parts of Folium Et Cacumen Murrayae, 10 parts of Fructus Hordei Germinatus (parched to brown)s, 25 parts of Fructus Setariae Germinatus (parched to brown).
The Chinese medicine of embodiment 2 ~ 4 can be prepared from by following method:
(1) Radix Puerariae, Cortex Ponciri trifoliatae, Diplazium lanceum (Thunb) coarse powder are extracted to volatile oil with vapor distillation respectively, and mixing for standby use after collecting;
(2) Fructus Setariae Germinatus (parched to brown), Fructus Hordei Germinatus (parched to brown) were pulverized to 150 mesh sieves, and became fine powder standby;
(3) Semen Litchi, Fructus Polygoni Orientalis, Radix Platycodonis, Caulis Trachelospermi, Retinervus Luffae Fructus, Rhizoma Paridis, Folium Et Cacumen Murrayae mix and add 10 times of water yields, decoct with water 2 times, and each 1 hour, collecting decoction, standing; Then toward 95% the ethanol that adds 3 ~ 4 times of medicinal liquids in decocting liquid, standing 15 minutes, then with 3000rpm/min centrifugal 20 minutes, get precipitation, spray drying, draw just material;
(4) gained volatile oil in step 1 is sprayed in the first material of step 3 gained, add gained fine powder in step 2 to mix, cross 60 mesh sieves, sterilizing is standby.
During use, get appropriate mature vinegar and dress affected part.
Effective combination of said medicine, coordinate mutually, invigorates blood circulation, eliminates the phlegm, eliminating stagnation, dredging collateral, effectively reach the purpose of diaphyseal aclasis, and side effect is less.The above results is the clinical data sufficient proof, and interrelated data is as follows.
1 object and method.
1.1 object.
1.1.1 case is selected: in January, 2008 ~ 2012 a year December is diagnosed as diaphyseal aclasis 90 examples, is the outpatient, is divided into matched group, hot-wet compress group and vinegar and dresses group.Matched group 30 examples, age 12 ~ 19(14.32 ± 4.71) year; Hot-wet compress group 30 examples, age 13 ~ 20(16.89 ± 6.09) year; Vinegar dresses group 30 examples, age 12 ~ 20(15.48 ± 6.11) year.Three groups of patients all have arthralgia or malaise symptoms in various degree, front comparison on sex, age, the state of an illness, the difference not statistically significant (P > 0.05), there is comparability.
1.1.2 diagnostic criteria: with reference to " osteopathia " (the 5th edition), all cases is all clarified a diagnosis according to medical history, physical examination, X-ray inspection, and cartilage oligomeric matrix albumen (COMP) detects all negative.
1.2 method.
1.2.1 Therapeutic Method: matched group is taked symptomatic treatment, exempts to bear a heavy burden, as arthralgia adopts ibuprofen oral.The hot-wet compress group on the treatment of control group scheme with gained decoction oral in the embodiment of the present invention 1,2 times/d.Vinegar dress group on the treatment of control group scheme with gained medicated powder in the embodiment of the present invention 2, get appropriate mature vinegar and dress affected part, 2 times/d.Within 1 month, be 1 course for the treatment of, after 3 courses for the treatment of, add up curative effect.The group that dresses vinegar continues by this therapeutic scheme treatment, and be 1 year total course for the treatment of, and matched group and vinegar dress group and carries out the X-ray check after 1 year.
1.2.2 observation item: carry out symptom main suit's record, carry out respectively the X-ray check when 3m and 12m, calculate the incidence rate of long bone of limbs cripetura or deformity.Definite method of long bone of limbs cripetura is comply with " osteopathia ", by a year growth ratio, contrasts this age bracket balanced growth ratio, as in extremity any one side year growth ratio be judged as and the long bone cripetura occurs lower than 10% of balanced growth ratio.
1.2.3 statistical analysis: SPSS 13.0 carries out statistical analysis.Measurement data is checked with t, the enumeration data chi-square criterion.
2 results.
2.1 respectively organize performance: after 3 courses for the treatment of, what the hot-wet compress group finally completed whole-course treatment is 22 examples, completion rate 73.33%, and the case that comes off all can not adhere to due to complex operation using.Vinegar dresses group completion rate 100%.
2.2 before and after treatment, X-ray checks relatively (after treating 3 months): matched group 36.67% patient occurs that the tumor body becomes large, and the hot-wet compress group is 13.64%, and it is 16.67% that vinegar dresses group.The bad progress incidence rate that vinegar dresses group and hot-wet compress group is starkly lower than matched group (P<0.05).Illustrate that the present invention can control PD.
2.3 before and after treatment, X-ray checks relatively (after treating 1 year): matched group 53.33% patient occurs that the tumor body becomes large or quantity and increases, and vinegar to dress group be 20.00%, vinegar dresses group and is starkly lower than matched group (P<0.05).Long bone of limbs cripetura or deformity appear in matched group 36.67% patient, and vinegar to dress group be 13.33%, the incidence rate that vinegar dresses group long bone of limbs cripetura or deformity is starkly lower than matched group (P<0.05).
2.4 adverse reaction rate relatively: vinegar dresses group and the hot-wet compress group has no obvious adverse reaction.
3. conclusion.
This result of study shows, takes hot-wet compress group of the present invention and vinegar and dresses the group obvious effective rate apparently higher than matched group, and can prevent that the diaphyseal aclasis state of an illness from further developing.Long-term taking medicine, contribute to reduce the incidence rate of long bone of limbs cripetura or deformity.
Claims (2)
1. a pharmaceutical composition for the treatment of diaphyseal aclasis, is characterized in that being prepared from by the crude drug of following weight proportion: 10 ~ 30 parts of Semen Litchis, 6 ~ 12 parts of Cortex Ponciri trifoliatae, 6 ~ 12 parts of Caulis Trachelospermis, 6 ~ 12 parts of Retinervus Luffae Fructuss, 1 ~ 5 part of Folium Et Cacumen Murrayae, 3 ~ 10 parts of Fructus Polygoni Orientaliss, 6 ~ 12 parts of Radix Platycodoniss, 6 ~ 12 parts of Radix Puerariaes, 6 ~ 12 parts of Rhizoma Paridis, 3 ~ 10 parts of Diplazium lanceum (Thunb)s, 3 ~ 10 parts of Fructus Hordei Germinatus (parched to brown)s, 10 ~ 25 parts of Fructus Setariae Germinatus (parched to brown).
2. a kind of pharmaceutical composition for the treatment of diaphyseal aclasis according to claim 1, is characterized in that being prepared from by the crude drug of following weight proportion: 20 parts of Semen Litchis, 10 parts of Cortex Ponciri trifoliatae, 10 parts of Caulis Trachelospermis, 10 parts of Retinervus Luffae Fructuss, 2 parts of Folium Et Cacumen Murrayae, 6 parts of Fructus Polygoni Orientaliss, 10 parts of Radix Platycodoniss, 10 parts of Radix Puerariaes, 10 parts of Rhizoma Paridis, 6 parts of Diplazium lanceum (Thunb)s, 6 parts of Fructus Hordei Germinatus (parched to brown)s, 20 parts of Fructus Setariae Germinatus (parched to brown).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310107794.7A CN103191343B (en) | 2013-03-31 | 2013-03-31 | Pharmaceutical composition for treating diaphyseal aclasis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310107794.7A CN103191343B (en) | 2013-03-31 | 2013-03-31 | Pharmaceutical composition for treating diaphyseal aclasis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103191343A true CN103191343A (en) | 2013-07-10 |
| CN103191343B CN103191343B (en) | 2015-04-08 |
Family
ID=48714276
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310107794.7A Expired - Fee Related CN103191343B (en) | 2013-03-31 | 2013-03-31 | Pharmaceutical composition for treating diaphyseal aclasis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103191343B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103142901A (en) * | 2013-03-31 | 2013-06-12 | 李青 | Nursing medicine for diaphyseal aclasis |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101537090A (en) * | 2009-04-30 | 2009-09-23 | 任平乐 | Pharmaceutical composition for treating lumbar intervertebral disc protrusion, preparation method and use thereof |
| CN101549137A (en) * | 2009-02-23 | 2009-10-07 | 喻政民 | Chinese medicine preparation for treating bone joint disease |
| CN101647576A (en) * | 2009-09-03 | 2010-02-17 | 辽宁鹿源参茸饮片有限公司 | Deer bone powder and preparation method thereof |
-
2013
- 2013-03-31 CN CN201310107794.7A patent/CN103191343B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101549137A (en) * | 2009-02-23 | 2009-10-07 | 喻政民 | Chinese medicine preparation for treating bone joint disease |
| CN101537090A (en) * | 2009-04-30 | 2009-09-23 | 任平乐 | Pharmaceutical composition for treating lumbar intervertebral disc protrusion, preparation method and use thereof |
| CN101647576A (en) * | 2009-09-03 | 2010-02-17 | 辽宁鹿源参茸饮片有限公司 | Deer bone powder and preparation method thereof |
Non-Patent Citations (4)
| Title |
|---|
| 刘维恒: "遗传性多发性骨软骨瘤――两组病例家族成员随访调查", 《临床放射学杂志》, vol. 4, no. 3, 20 June 1985 (1985-06-20), pages 163 - 164 * |
| 张壮岱 等: "多发性骨软骨瘤病伴椎管内骨软骨瘤1例", 《中国矫形外科杂志》, vol. 7, no. 8, 30 August 2000 (2000-08-30), pages 754 * |
| 张德强 等: "多发性骨软骨瘤病", 《中华小儿外科杂志》, vol. 24, no. 2, 20 April 2003 (2003-04-20), pages 182 - 183 * |
| 陈福贵: "理气活血汤治疗肋软骨炎60例", 《中国中医药科技》, vol. 2, no. 4, 31 December 1995 (1995-12-31), pages 47 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103142901A (en) * | 2013-03-31 | 2013-06-12 | 李青 | Nursing medicine for diaphyseal aclasis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103191343B (en) | 2015-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101095785B (en) | Chinese traditional medicine composition for treating arthritis hyperosteogeny intervertebral disc protrusion | |
| CN101108226A (en) | Medicament treating rheumatism, rheumatoid, woman's wind, osteoproliferation and slipped disc illness | |
| CN1824009B (en) | Multipurpose medicinal composition capable of oral administration and external use | |
| CN103191343B (en) | Pharmaceutical composition for treating diaphyseal aclasis | |
| CN103191342B (en) | Method for preparing diaphyseal aclasis nursing substance | |
| CN103142897B (en) | Medicine used after esophageal achalasia operation | |
| CN103520652B (en) | Traditional Chinese medicine composition for treating liver cancer | |
| CN105688059A (en) | Traditional Chinese medicine preparation with folium artemisiae argyi for treating osteoproliferation through external application | |
| CN103191340A (en) | Drug for nursing osteochondroma | |
| CN103157032B (en) | Postoperative medicine for chondroblastoma | |
| CN104644841B (en) | Kazak medicine composition for treating neck, shoulder, waist and leg pain | |
| CN103142898B (en) | Preparation method of medicine used after esophageal achalasia operation | |
| CN103157040A (en) | Pharmaceutical composition for treating multiple osteoenchondroma | |
| CN103191345B (en) | Postoperative drug for chronic peptic ulcer and esophagitis syndrome | |
| CN103142901A (en) | Nursing medicine for diaphyseal aclasis | |
| CN103157046A (en) | Preparation method of medicine for treating diaphyseal aclasis | |
| CN103191341A (en) | Method for preparing osteochondroma nursing substance | |
| CN105998512A (en) | Pharmaceutical composition for the treatment of femoral shaft fracture and preparation method thereof | |
| CN103142899A (en) | Preparation method of drug for treating spondyloepiphyseal dysplasia | |
| CN103157031A (en) | Preparation method of postoperative medicine for chondroblastoma | |
| CN104771529A (en) | Drug for treating traumatic arthritis caused by deficiencies in liver and kidney and preparation method thereof | |
| CN103157041A (en) | Preparation method of medicine for treating multiple osteoenchondroma | |
| CN103191335B (en) | Pharmaceutical composition for treating esophageal achalasia | |
| CN103157042B (en) | Medicament for treating Barrett syndrome | |
| CN104083588A (en) | Orthopaedic medicinal liquor for treating lumbar muscle strain and swelling and hard symptom and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Dong Guangyu Inventor after: Wang Dong Inventor after: Xu Jinlin Inventor before: Dong Guangyu Inventor before: Wang Dong |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: DONG GUANGYU WANG DONG TO: DONG GUANGYU WANG DONG XU JINLIN |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150408 Termination date: 20160331 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |